| ￥3000 | |
| Z05589-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 49.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of LILRA6/CD85b/ILT8, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
LILRA6/CD85b/ILT8, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95% »
| Target Background | The LILRs are a family of receptors that regulate the activities of myelomonocytic cells. Specific allelic variants of two related members of the LILR family, LILRB3 and LILRA6, interact with a ligand exposed on necrotic glandular epithelial cells. The extracellular domains of LILRB3 and LILRA6 are very similar and their genes are highly polymorphic. |
| Synonyms | 7M1; CD85b; ILT8; LILRA6; Pira3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
